Alumis' Meteoric Rise To $20 From $5 In Just 60 Days On Plaque Psoriasis Trial Results

Alumis reported positive topline Phase III results for Envudeucitinib in ONWARD1 and ONWARD2, with roughly 65% of patients achieving PASI90 and over 40% achieving PASI100 at Week 24 on average across the two trials, and patients rolling into the ONWARD3 long-term extension. The company plans an NDA submission in the second half of the year; Envudeucitinib competes in the TYK2 class where Bristol Myers Squibb's Sotyktu is currently the sole approved therapy (Sotyktu sales: $170M in 2023, $246M in 2024, ~$206M in first 9 months of 2025). Shares have reacted, touching an intraday all-time high of $23 and closing at $22.11 (+4.84%), and Alumis also expects Phase 2b SLE topline data in Q3 2026.

Analysis

Market structure: Positive ONWARD toplines materially expand the oral TYK2 category and create a direct winner in ALMS (Envudeucitinib) if FDA accepts the NDA H2 2026. Primary beneficiaries: ALMS equity and any specialty CRO/manufacturing suppliers; incumbent BMY (Sotyktu) faces share erosion — realistic TALKS: ALMS could capture 10-30% of the TYK2 revenue pool within 2–3 years if label and pricing are comparable. Pricing power across IL-23/IL-17 biologics is unlikely to compress materially short-term, but oral adoption alters payer formulary dynamics.

Risk assessment: Tail risks include an FDA Complete Response Letter or late safety signal from ONWARD3/LTE — low probability but >30% value impact if realized. Timeline: immediate (days) = elevated IV and 20–40% intraday swings; short-term (weeks–months) = NDA acceptance, med‑meeting data releases; long-term (12–36 months) = commercial launch, payer contracting and lupus Phase 2b readout (Q3 2026). Hidden dependencies: formulary negotiations, manufacturing scale-up, and potential dilution to fund commercialization (equity raise could dilute 15–35% depending on needs).

Trade implications: Tactical core-long in ALMS sized 2–3% of NAV, phased over 4 weeks ahead of the med‑meeting and NDA filing, with a protective -40% stop; add to 4–5% on FDA acceptance. Pair trade: long ALMS 2% vs short BMY 0.5–1% to hedge system-wide immunology demand risk. Options: buy a capped Jul‑2026 20/40 call spread equal to 0.5–1.0% NAV to lever upside into NDA with defined downside; buy 6–9 month 15 puts (protect 10–30% tail risk) if delta-hedged.

Contrarian angles: Consensus prizes efficacy but underprices access friction — payers may prefer established Sotyktu with real-world safety, keeping ALMS uptake slow (realistic adoption curve: 10–15% of eligible patients in year 1 of launch). The 4x+ rally from $5.5 to $23 likely overstates near-term commercialization probability; historical parallels show second-in-class entries often trade back 30–60% if reimbursement lags. Unintended consequence: expensive EU/US launches and fortifying rebates by incumbents could compress ALMS 2027–2028 free cash flow; treat current valuation as event‑driven, not permanent market-share capture.

Key Decisions for Investors

• Establish a phased long position in ALMS (ticker ALMS) equal to 2–3% of NAV over the next 4 weeks (buy tranches at $18–22 then $14–18 on pullbacks); set a hard stop at -40% from average entry and plan to increase to 4–5% on FDA acceptance (PDUFA/acceptance expected H2 2026).
• Implement a hedged pair: long ALMS 2% vs short BMY (ticker BMY) 0.5–1% to isolate Envudeucitinib-specific upside while offsetting class/market risk; rebalance within 5 trading days of NDA decision or LTE safety signal.
• Use options to define risk: buy a Jul‑2026 ALMS 20/40 call spread sized to 0.5–1.0% NAV to capture upside into NDA (max loss = premium) and simultaneously buy 6–9 month ALMS 15 puts (size 0.5% NAV) to protect tail risk if clinical/regulatory news is negative.
• Prepare to reduce biotech cyclic exposure: trim non-event-driven small-cap immunology longs by 1–3% of NAV to fund ALMS exposure; if ONWARD3/LTE shows adverse safety or NDA delayed >3 months, exit ALMS completely within 5 trading days and redeploy to cash or longs with positive cash flow.